A Preview Of Oncolytics Biotech's Earnings
Portfolio Pulse from Benzinga Insights
Oncolytics Biotech (NASDAQ:ONCY) is scheduled to release its quarterly earnings report on March 7, 2024, with analysts expecting an EPS of $-0.11. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's EPS miss leading to no change in stock price. Shares are currently trading at $1.03, down 22.56% over the last year. Investors are looking for positive guidance for the next quarter.
March 06, 2024 | 7:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oncolytics Biotech is expected to report an EPS of $-0.11 for the latest quarter. The company's stock price has been negatively impacted over the last year, with a 22.56% decrease. Investors are focused on future guidance.
Given the mixed past performance and the significant annual decline in stock price, the upcoming earnings report and particularly the future guidance provided by Oncolytics Biotech will be crucial for investors. The expectation of an EPS of $-0.11 aligns with recent trends, but the market's reaction will heavily depend on the forward-looking statements. The neutral score reflects the uncertainty of the impact of the earnings report on the stock price, considering both the historical performance and the anticipation surrounding the future guidance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100